Rani Therapeutics Holdings, Inc. - Class A (RANI)
RANI moved a median of -0.25% 30 minutes after news, and -0.71% by the close. How RANI actually reacts to news — the realized, point-in-time move the market made, measured across 236 labeled events over the last three years with zero look-ahead.
RANI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.07% | 55% | 233 |
| 30-min | -0.25% | 43% | 235 |
| 60-min | 0.00% | 52% | 235 |
| to close | -0.71% | 34% | 235 |
| Middle 50% of RANI reactions | -3.20% to +1.71% |
|---|---|
| Median reaction (30-min) | -0.25% |
| Measured reactions | 236 |
Half of all Rani Therapeutics Holdings, Inc. - Class A news events land between -3.20% and +1.71% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RANI reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 13 | +3.45% | 77% | -0.24% |
| Rating reiterations | 37 | -0.65% | 32% | -0.65% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how RANI ranks against every other measured name →
That’s how RANI usually reacts — get an email when it moves on news →Email me when RANI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RANI's baseline. Nothing else.
Recent RANI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Rani Therapeutics to Participate in the Chardan Healthcare Conference | Press release | GlobeNewswire | -0.56% | -6.13% | |
| Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) | Press release | GlobeNewswire | -0.99% | -7.75% | |
| Rani Therapeutics to Participate in Upcoming September Conferences | Press release | GlobeNewswire | -0.34% | -0.06% | |
| Form 10-Q Rani Therapeutics Holdin For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.95% | +1.93% | |
| Form 8-K Rani Therapeutics Holdin For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.95% | +1.93% | |
| Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update | Press release | GlobeNewswire | +1.95% | +1.93% | |
| Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference | Press release | GlobeNewswire | -0.95% | — | |
| Form 8-K Rani Therapeutics Holdin For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | +2.75% | +2.35% | |
| Rani Therapeutics Appoints Michelle Gilson to Board of Directors | Press release | GlobeNewswire | +2.75% | +2.35% | |
| Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.51% | +4.54% | |
| Form S-8 Rani Therapeutics Holdin | SEC filing · Form S-8 | SEC EDGAR | -3.02% | -1.41% | |
| Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing | Press release | GlobeNewswire | +0.28% | -0.75% | |
| Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates | Press release | GlobeNewswire | -1.20% | -3.21% | |
| Form 8-K Rani Therapeutics Holdin For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +1.33% | +1.39% | |
| Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer | Press release | GlobeNewswire | +0.00% | +3.34% | |
| Form 8-K Rani Therapeutics Holdin For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +1.54% | -0.08% | |
| Form 8-K Rani Therapeutics Holdin For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +1.37% | +3.83% | |
| Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -2.92% | -4.89% | |
| Form 10-Q Rani Therapeutics Holdin For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +4.67% | -8.27% | |
| Form 8-K Rani Therapeutics Holdin For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +4.67% | -8.27% | |
| Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition | Press release | GlobeNewswire | +4.67% | -8.27% | |
| Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference | Press release | GlobeNewswire | -2.73% | -4.54% | |
| Form ARS Rani Therapeutics Holdin For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.35% | +3.96% | |
| Form DEF 14A Rani Therapeutics Holdin For: May 28 | SEC filing · Form DEF | SEC EDGAR | +1.35% | +3.96% | |
| Form DEFA14A Rani Therapeutics Holdin | SEC filing · Form DEFA14A | SEC EDGAR | +1.35% | +3.96% | |
| Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy | Press release | GlobeNewswire | -0.91% | -7.45% | |
| Form 10-K Rani Therapeutics Holdin For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.75% | -23.53% | |
| Form 8-K Rani Therapeutics Holdin For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -3.75% | -23.53% | |
| Form S-8 Rani Therapeutics Holdin | SEC filing · Form S-8 | SEC EDGAR | -3.75% | -23.53% | |
| Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update | Press release | GlobeNewswire | -3.75% | -23.53% | |
| Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization | Press release | GlobeNewswire | -6.57% | -11.47% | |
| Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -3.45% | -2.59% | |
| Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer | Press release | GlobeNewswire | +0.00% | -2.19% | |
| Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen | Press release | GlobeNewswire | -1.42% | -0.71% | |
| Form 8-K Rani Therapeutics Holdin For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | -1.45% | |
| Form DEF 14C Rani Therapeutics Holdin For: Dec 05 | SEC filing · Form DEF | SEC EDGAR | -0.39% | -3.11% | |
| Form EFFECT Rani Therapeutics Holdin | SEC filing · Form EFFECT | SEC EDGAR | +0.67% | +6.80% | |
| Form PRE 14C Rani Therapeutics Holdin For: Nov 25 | SEC filing · Form PRE | SEC EDGAR | +1.86% | +0.62% | |
| Rani Therapeutics to Participate in the Evercore Healthcare Conference | Press release | GlobeNewswire | -3.59% | -3.59% | |
| Form D Rani Therapeutics Holdin | SEC filing · Form D | SEC EDGAR | +1.49% | -7.46% | |
| Form S-3 Rani Therapeutics Holdin | SEC filing · Form S-3 | SEC EDGAR | +1.49% | -7.46% | |
| Form 10-Q Rani Therapeutics Holdin For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.82% | +3.59% | |
| Form 8-K Rani Therapeutics Holdin For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +2.82% | +3.59% | |
| Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update | Press release | GlobeNewswire | +2.82% | +3.59% | |
| Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025 | Press release | GlobeNewswire | -0.04% | -9.94% | |
| Form 8-K Rani Therapeutics Holdin For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | +7.76% | -7.77% | |
| Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules | Press release | GlobeNewswire | +3.91% | -10.35% | |
| Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors | Press release | GlobeNewswire | +3.91% | -10.35% | |
| Form 8-K Rani Therapeutics Holdin For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | +19.71% | |
| Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules | Press release | GlobeNewswire | +0.72% | +19.71% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RANI section they belong to.
Where else RANI is measured.
RANI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Rani Therapeutics Holdings, Inc. - Class A's median reaction calculated?
Every labeled RANI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 236 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of RANI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RANI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.